---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-040073"
form_type: "8-K"
ticker: "INFU"
cik: "0001337013"
company_name: "InfuSystem Holdings, Inc"
filed_at: "2024-09-11T23:59:59+00:00"
generated_at: "2026-05-31T05:23:52.304773+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# InfuSystem and Sanara secure exclusive US distribution deal for ChemoMouthpiece oral cryotherapy device

## Summary
- SI Technologies, a 50/50 JV between InfuSystem and Sanara, will be exclusive US distributor of ChemoMouthpiece's FDA 510(k)-cleared oral mucositis device.
- Sanara invested $5 million for a 6.6% ownership stake in ChemoMouthpiece; SI Technologies has a purchase option on the US business through January 2029.
- Product targets 500,000–1,000,000 annual oral mucositis patients; estimated US market exceeds $600 million.
- InfuSystem's existing oncology sales force will market the device to ~3,000 cancer centers.
- AMA issued a new CPT code (effective July 2024) for reimbursement of the oral cryotherapy procedure.

## SEC filing metadata
- accession: 0001628280-24-040073
- form_type: 8-K
- ticker: INFU
- cik: 0001337013
- company_name: InfuSystem Holdings, Inc
- filed_at: 2024-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1337013/000162828024040073/0001628280-24-040073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1337013/000162828024040073/infu-20240911.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-040073
- JSON: https://secwatch.observer/filing/0001628280-24-040073.json
- Plain text: https://secwatch.observer/filing/0001628280-24-040073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.